Human T-cells recognise N-terminally Fmoc-modified peptide
- Author(s)
- Mannering, SI; Purcell, AW; Honeyman, MC; McCluskey, J; Harrison, LC;
- Details
- Publication Year 2003-09-08,Volume 21,Issue #25-26,Page 3638-3646
- Journal Title
- VACCINE
- Publication Type
- Journal Article
- Abstract
- We aimed to generate T-cell clones specific for human pre-proinsulin. An HLA DQ8, CD4(+) T-cell clone that recognised a 10mer (C65-A9) peptide from pre-proinsulin was isolated. Further analysis revealed that the clone responded neither to recombinant proinsulin nor to re-synthesised C65-A9 peptide. Analysis of the original peptide revealed minor contamination (<0.5%) with an N-terminal Fmoc adduct. This peptide was synthesised and shown to stimulate the clone. Thus, Fmoc-modified peptides, which are common contaminants in synthetic peptides, can stimulate human CD4(+) T-cells. This finding has important implications for the use of synthetic peptides in screening and epitope mapping studies and their use as vaccines in humans. (C) 2003 Elsevier Science Ltd. All rights reserved.
- Publisher
- ELSEVIER SCI LTD
- Keywords
- ACETYLCHOLINE-RECEPTOR; CROSS-REACTIVITY; EPITOPES; RESPONSES; VACCINES; DETERMINANTS; REDUCTION; GAMMA; VIRUS; IDDM
- Publisher's Version
- https://doi.org/10.1016/S0264-410X(03)00402-X
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2003-09-08 12:00:00